The makers of the popular Oura Ring have withdrawn their application for a $15 billion stock market listing in the United States, just days after initially announcing the financial move. The company cited ongoing instability in the initial public offering (IPO) market as the primary reason for postponing the flotation, though no new timeline was provided.
Tom Hale, Oura’s chief executive, described the decision as a strategic pause rather than a failure. “An IPO is just one step in our journey,” Hale stated, adding that the firm retains “the luxury of choosing our moment” before entering the public markets.
The withdrawal follows similar delays by other major corporations. Earlier this month, US nuclear technology firm Holtec International also called off its flotation, pointing to a convergence of negative factors including rising energy costs, global trade tensions, and inflation concerns that have prompted central banks to raise interest rates. Notably, the yield on 10-year US debt recently reached its highest level since 2007.
Samuel Kerr, global head of equity capital markets at Mergermarket, highlighted the stark shift in financial conditions. “What is now clear is we are in a very different IPO market to the one we envisaged just a few weeks ago,” he said.
Had the listing proceeded, Oura intended to offer shares priced between $40 and $44 on the Nasdaq exchange, aiming to raise up to $2.2 billion. The company reported strong financial growth, with pre-tax profits reaching $70 million on sales of $1.2 billion for the nine months ending June 2026, up from a $6.2 million pre-tax profit in the previous fiscal year.
Founded in Finland in 2013 and headquartered in San Francisco, Oura produces smart rings starting at $300 that monitor heart rate, sleep patterns, and other biometrics. The company recently faced a class action lawsuit filed by the Clarkson Law Firm in August, which alleged false advertising regarding the accuracy of its sleep tracking technology. A spokesperson for Oura maintained that the IPO delay is unrelated to the legal proceedings, reaffirming confidence in their scientific data and noting that their devices estimate sleep stages using multiple physiological signals such as heart rate variability and temperature.
Wait, it’s $300 and up? I guess that explains why I haven’t converted my gym friends yet.
Yields at seven-year highs really kill growth valuations. Smart move by Hale to hit the brakes.
Interesting timing with that class action lawsuit looming. Hope the legal trouble isn’t the real reason behind this pause.
The IPO window is clearly shut tight right now. Good call to wait rather than take a bad price.
Still rocking my Oura ring after three years. Hope they get back to the markets soon!